Prior studies showed that polyglutamine-expanded androgen receptor (AR) is aberrantly acetylated and that deacetylation of the mutant AR by overexpression of nicotinamide adenine dinucleotide–dependent (NAD
+
-dependent) sirtuin 1 is protective in cell models of spinal and bulbar muscular atrophy (SBMA). Based on these observations and reduced NAD
+
in muscles of SBMA mouse models, we tested the therapeutic potential of NAD
+
restoration in vivo by treating postsymptomatic transgenic SBMA mice with the NAD
+
precursor nicotinamide riboside (NR). NR supplementation failed to alter disease progression and had no effect on increasing NAD
+
or ATP content in muscle, despite producing a modest increase of NAD
+
in the spinal cords of SBMA mice. Metabolomic and proteomic profiles of SBMA quadriceps muscles indicated alterations in several important energy-related pathways that use NAD
+
, in addition to the NAD
+
salvage pathway, which is critical for NAD
+
regeneration for use in cellular energy production. We also observed decreased mRNA levels of nicotinamide riboside kinase 2 (
Nmrk2
), which encodes a key kinase responsible for NR phosphorylation, allowing its use by the NAD
+
salvage pathway. Together, these data suggest a model in which NAD
+
levels are significantly decreased in muscles of an SBMA mouse model and intransigent to NR supplementation because of decreased levels of
Nmrk2
.